🔴 Aytu BioScience is trading 5% down in after-hours trading as full-year revenue and adjusted EBITDA declined

Aytu BioScience is trading at $2.16, down 5.46%, as investors weigh mixed fiscal 2026 results.

• Q4 revenue rose 6.4% to $16.1 million; full-year revenue fell 13.3% to $57.6 million.
• ADHD sales declined, and adjusted EBITDA decreased to $0.5 million from $2.0 million.
• Management provided no specific fiscal 2027 financial targets, only qualitative expectations for improving profitability. No separate September 23 company-specific announcement was identified.